Drug intelligence / Profile preview

agriflu

Development stage
Approved
Lead developer
CSL Seqirus
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Agriflu is an inactivated trivalent influenza virus vaccine containing purified surface antigens of influenza viruses type A and B. It is indicated for active immunization to prevent disease caused by the specific influenza virus subtypes A and type B contained in the vaccine. The vaccine works by stimulating the immune system to produce antibodies against these viral strains, thereby providing protection against seasonal influenza. Agriflu is administered as an intramuscular injection and is approved for use in adults 18 years of age and older (in the US), though it has also been indicated for persons 6 months of age and older in some regions such as Canada. The composition of Agriflu changes annually based on recommendations from health authorities to match circulating strains[2][3][5][6].

Brand names
Agriflu
Other names
Influenza Virus Vaccine, surface antigen, inactivated
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on agriflu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on agriflu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call